Craft

Allogene Therapeutics

Stock Price

$2.7

2024-05-22

Market Capitalization

$555.4 M

2024-05-22

Revenue

$243 K

FY, 2022

Allogene Therapeutics Summary

Company Summary

Overview
Allogene Therapeutics is a clinical-stage biotechnology company developing allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer. AlloCAR T products are engineered from the T cells of healthy donors and can target specific antigens on cancer cells.
Type
Public
Status
Active
Founded
2018
HQ
South San Francisco, CA, US | view all locations
Website
https://allogene.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • David Chang

    David Chang, President, Chief Executive Officer and Co-Founder, Director

  • Tim Moore

    Tim Moore, Executive Vice President, Chief Technical Officer

  • Geoffrey Parker

    Geoffrey Parker, Executive Vice President, Chief Financial Officer

  • Susie Lundeen

    Susie Lundeen, Chief People Officer

Operating MetricsView all

Office and Laboratory Space, square feet

200.9K
9.7%

FY, 2019

Phase I Trials Products

4
300.0%

FY, 2019

Pre-Clinical Phase Products

8
14.3%

FY, 2019

LocationsView all

1 location detected

  • South San Francisco, CA HQ

    United States

    210 E Grand Ave

Allogene Therapeutics Financials

Summary Financials

Revenue (Q1, 2024)
$22.0K
Net income (Q1, 2024)
($65.0M)
Cash (Q1, 2024)
$51.0M
EBIT (Q1, 2024)
($69.5M)
Enterprise value
$600.2M

Footer menu